verve records - Search News

News

Lilly to buy gene-editing partner Verve

Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to boost its pipeline of experimental medicines beyond its blockbuster weight-loss and diabetes drugs.

UPI on MSN · 1d

Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

Pharmaceutical Technology on … · 14h

Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn.

1don MSN

Eli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know.

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

11h

Lock In The 81.5% Run - Initiating Verve With A Sell

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

PMLive12h

Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

1don MSN

Why Verve Therapeutics Stock Is Skyrocketing Today

Shares of Verve Therapeutics ( VERV 76.56%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly ( LLY -0.90%) and Verve Therapeutics announced a "definitive ...

Verve Therapeutics downgraded to Hold from Buy at Canaccord

Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results